Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss for the year	$ (22,661)	$ (38,298)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of intangible assets		2
Depreciation of property and equipment	60	30
Impairment of in-process research and development		16,094
Change in fair value of milestone liability	(19)	(6)
Interest expense		30
Amortization of deferred loan costs		94
Warrants issued for services	35	569
Stock option expense	2,248	5,276
Changes in operating assets and liabilities
Prepaid expenses, deposits and other	(722)	(381)
Clinical trial deposits	(500)	(2,100)
Accounts payable and accrued liabilities	1,007	(67)
Related party payables	160	(103)
Net cash used in operating activities	(20,392)	(18,860)
Cash flows from investing activities
Cash acquired on merger with Adgero		969
Purchase of equipment		(8)
Proceeds on sale of equipment		3
Net cash provided by investing activities		964
Cash flows from financing activities
Net proceeds from the issuance of shares and warrants	21,569	21,598
Warrants exercised for cash	74	4,404
Stock options exercised for cash		77
Proceeds from loan		500
Repayment of loan		(500)
Interest paid		(30)
Series A preferred cash dividend	(8)	(8)
Net cash provided by financing activities	21,635	26,041
Increase in cash and cash equivalents	1,243	8,145
Cash and cash equivalents – beginning of year	10,537	2,392
Cash and cash equivalents – end of year	$ 11,780	$ 10,537